31,623 Shares in Aldeyra Therapeutics, Inc. $ALDX Acquired by Ballast Inc.

Ballast Inc. bought a new position in shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 31,623 shares of the biotechnology company’s stock, valued at approximately $121,000.

Other large investors have also added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC acquired a new stake in Aldeyra Therapeutics during the first quarter worth approximately $63,000. Invesco Ltd. boosted its holdings in Aldeyra Therapeutics by 1,575.7% in the first quarter. Invesco Ltd. now owns 501,137 shares of the biotechnology company’s stock worth $2,882,000 after acquiring an additional 471,231 shares in the last quarter. Wellington Management Group LLP bought a new position in Aldeyra Therapeutics in the first quarter worth approximately $675,000. Strs Ohio bought a new position in Aldeyra Therapeutics in the first quarter worth approximately $440,000. Finally, Pallas Capital Advisors LLC bought a new position in Aldeyra Therapeutics in the second quarter worth approximately $68,000. Institutional investors and hedge funds own 59.71% of the company’s stock.

Aldeyra Therapeutics Stock Down 2.4%

ALDX stock opened at $5.26 on Monday. Aldeyra Therapeutics, Inc. has a twelve month low of $1.14 and a twelve month high of $7.20. The stock’s 50 day moving average is $5.44 and its 200-day moving average is $4.02. The firm has a market capitalization of $315.07 million, a PE ratio of -6.19 and a beta of 0.83.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Thursday, August 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.05. On average, equities research analysts anticipate that Aldeyra Therapeutics, Inc. will post -0.92 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ALDX has been the topic of several recent research reports. Zacks Research upgraded Aldeyra Therapeutics to a “hold” rating in a report on Friday, August 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aldeyra Therapeutics in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Aldeyra Therapeutics presently has a consensus rating of “Hold” and an average target price of $9.50.

Insider Buying and Selling at Aldeyra Therapeutics

In other news, insider Stephen Machatha sold 22,073 shares of the firm’s stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $5.15, for a total value of $113,675.95. Following the transaction, the insider owned 221,799 shares in the company, valued at $1,142,264.85. This trade represents a 9.05% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 8.50% of the stock is owned by corporate insiders.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.